Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) Net Margin (2023)

Contineum Therapeutics has reported Net Margin over the past 1 years, most recently at 83.13% for Q2 2023.

  • Quarterly results put Net Margin at 83.13% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 38.23% (changed N/A YoY), and the annual figure for FY2023 was 45.44%, changed.
  • Net Margin for Q2 2023 was 83.13% at Contineum Therapeutics, down from 5243.48% in the prior quarter.
  • Over the last five years, Net Margin for CTNM hit a ceiling of 5243.48% in Q1 2023 and a floor of 83.13% in Q2 2023.